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SUPPRESSION OF ALLOGRAFT REJECTION WITH FK506 
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Heterotopic heart and orthotopic liver grafts from ACI 
donors were transplanted to Lewis rat recipients that 
were treated with a 3 (or 4) day course of FK506 1M 
that was started on postoperative day 0, 2, 3, 4, 5, or 6. 
Hearts, which rejected after a median of 6 days in un-
treated controls, always had prolonged survival (median 
91 days) when treatment was started on postoperative 
day 4. The results were inferior when treatment was 
started earlier or later than this, but even when the first 
dose of FK506 was on postoperative day 5, one day 
before rejection was imminent in controls, the median 
survival was 50 days. The poorest results with a median 
graft survival of only 36 days were obtained when in-
jections were on days 0-3. Results were similar with 
liver grafts that rejected after a median time of 10 days 
in nontreated controls but that usually survived per-
manently after a 3 (or 4) day FK506 course starting on 
day 0,2,3, or 4. Therapy started on day 6 was too late. 
The novel immunosuppressive agent FK506 (originally 
FR900506) was discovered in 1984 (1, 2) and has become an 
object of considerable interest in the field of organ transplan-
tation. Prolongation of survival times has been demonstrated 
for skin, heart, kidney, or liver allografts, in rodents (3-7), dogs 
(8-11), subhuman primates (11,12), and humans (13). FK506 
is more potent than cyclosporine and has a similar mode of 
action, including inhibition of T lymphocyte response to stim-
ulation with mitogen, or stimulation with alloantigens in mixed 
lymphocyte reactions (14, 15). It inhibits the induction of 
allospecific human and mouse cytolytic T lymphocytes, and it 
suppresses IL-2 and gamma-IFN secretion and IL-2 receptor 
expression of the T lymphocytes (2, 14-17). 
What FK506 does not do is of equal interest. It does not at 
any concentration inhibit the B-cell-stimulating factor 2 driven 
proliferation of cloned B cells, nor does it inhibit IL-2-driven 
proliferation of cloned T cells (17). Thus, FK506 has been said 
to inhibit the proliferation of lymphocytes during the recogni-
tion and induction phase of the allograft reaction and not the 
proliferation seen subsequent to the production and binding of 
lymphokines. If this were its complete profile, the effectiveness 
of FK506 in preventing allograft rejection would depend upon 
administration of the drug very early in the posttransplantation 
period. 
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We have previously shown that a brief course of FK506 
treatment can induce prolonged cardiac allograft survival in 
rats (5) and liver or kidney survival in dogs (11, 12). In the 
present study, we have examined in more detail the effect of a 
3- or 4-day course of FK506 treatment on the subsequent 
survival of heart and liver allografts in rats. In a companion 
study (18), we have characterized the changes of the host 
immune response that result from this therapeutic approach. 
MATERIALS AND METHODS 
Animals. Inbred male rats were used in all experiments. Lewis rats 
(LEW) weighing 250-350 g (Harlan Sprague-Dawley Inc., Indianapolis, 
IN) were the recipients, and ACI rats weighing 150-250 g (Simonsen 
Laboratories, Gilroy, CAl were donors. All animals were maintained in 
conventional animal facilities with water and commercial rat chow 
provided ad libitum. 
FK506 administration. FK506 was provided as a crystalline powder 
from the Fujisawa Pharmaceutical Company, Ltd. (Osaka, Japan). It 
was dissolved in saline and administered once a day by intramuscular 
injection. The date and timing of FK506 is noted for each experimental 
group in Tables 1 and 2. 
Orthotopic liver transplantation. Liver allografting was performed 
with a modification of the method described by Kamada and Caine 
(19) using the simplified cuff technique for the portal and infrahepatic 
vena cava anastomosis. Recipient animals received Cefamandole Na-
fate (20 mg/day i.m.) (Eli Lilly and Company, Indianapolis, IN) for 3 
days postoperatively. 
Animals that died within 3 days after surgery were considered 
technical failures and were excluded from the analyzed experimental 
data; however, the success rate for all liver transplants in this study 
was more than 95%. Rejection was monitored by body weight and blood 
chemistry values (SGOT, SGPT, and total bilirubin). Rejection of the 
grafts resulted in death of the recipients, and at the time of death all 
grafts were examined histologically. 
Heterotopic heart transplantation. Cardiac allografting was per-
formed as described by Ono and Lindsay (20) and consisted of anas-
tomosis ofthe donor aorta and pulmonary artery to the recipient aorta 
and infrarenal vena cava. Heart grafts were palpated daily, and rejec-
tion was established by cessation of the heartbeat and confirmed by 
direct inspection at laparotomy and by histologic examination. 
Statistical analysis. Results were analyzed for statistical significance 
by Wilcoxon rank-sum test, and differences considered statistically 
significant if P<O.Ol. 
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RESULTS 
Survival in cardiac allografts. Untreated LEW recipients 
rejected ACI heart grafts with median graft survival time of 6 
days (group 1, Table 1). As we previously reported in a study 
on FK506 dose-response relations (5), treatment with daily 
intramuscular FK506 (1.28 mg/kg) for the first 2 weeks after 
grafting significantly prolonged graft survival (group 2, MST: 
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TABLE 1. Effect of FK506 on survival of heart grafts from ACI donors to LEW recipients 
Group Treatment 
1 
2 1.28 mg/kg days 0-13 
3 1.28 mg/kg days 0-13, 
then once a week for 5 
weeks 
4 1.28 mg/kg days 0, 1, 2 
5 1.28 mg/kg days 4, 5, 6 
6 1.28 mg/kg days 5, 6, 7 
7 1.28 mg/kg days 3, 4, 5, 6 
8 2.5 mg/kg days 4, 5, 6 
" Median graft survival time in days. 
b Group 2 vs. 3, 4, 5, 7, 8, N.S.; group 2 vs. 6, P=O.Ol. 
, Died with pulsating graft. 
N 
7 
6 
12 
6 
6 
6 
6 
6 
Graft survival (days) MST (days)" P value' 
6,6,6,6,6,7,7 6.0 
56,71,80,94,96,213' 87.0 0.01 
8,' 81,82,86,87,88,88, 88.0 0.001 
89, 93, 101, 110, 122 
23, 35, 36, 36, 58, 75 36.0 0.01 
23,51,89,93,98,146 91.0 0.01 
25,48,49,51,60,61 50.0 0.01 
71,71,72,76,79,81 74.0 0.01 
38,54,75,85,101,120 80.0 0.01 
TABLE 2. Effect of FK506 treatment on survival of liver grafts from ACI donors to LEW recipients 
Group Days of treatment" N Graft survival (days) MST (days) P v.alue 
1 10 9,9,9,9,10,10,10, 10.0 
11, 12, 13 
2 Days 0, 1, 2 6 >100x6 >100 0.001 
3 Days 2, 3, 4 6 9,b >100x5 >100 0.001 
4 Days 4, 5, 6 14 9,10,10, 12,>100X10 >100 0.01 
5 Days 6, 7, 8 6 9, 9, 10, 11, 12, 15 10.5 NS 
6 Days 3, 4, 5, 6 10 13,b >100x9 >100 0.001 
"FK506 was given by daily intramuscular injection (1.28 mg/kg/day). 
b Death due to infection. 
87.0 days, P<O.OI). Five additional weekly injections of FK506 
(1.28 mg/kg) (group 3) did not prolong the median graft survival 
time for the group, but it did reduce the time range in which 
rejection occurred (Table I). 
The timing of drug administration influenced the effective-
ness of treatment. Doses at postoperative days 4, 5, and 6 
(group 5) was as effective as a course of 2 or more weeks (groups 
2 and 3). Earlier (days 0, 1,2; group 4) or later treatment (days 
5, 6, 7; group 6) was less effective (Table I). Increasing the 
length of treatment (days 3, 4, 5, 6; group 7) or increasing the 
amount of drug administered (2.5 mg/kg/day; group 8) did not 
result in additional prolongation of graft survival (Table I). 
Survival in liver allografts. The untreated control ACI liver 
grafts were acutely rejected in nontreated LEW recipients in 
9-13 days (group I, Table 2). The longer survival with untreated 
liver versus untreated heart grafts was significant (P<O.OOI). 
Short-term treatment with 1.28 mg/kg i.m. FK506 was highly 
effective in prolonging liver survival when given on days 0-2 
(group 2); 2-4 (group 3); 4-6 (group 4); and 3-6 (group 6). 
Permanent liver graft acceptance was the rule in all groups in 
which treatment was started before day 5. Treatment started 
on day 6 (group 5) was too late, and survival was reduced to 
that in the untreated control group. 
Histopathology. In both the heart and liver grafts, the short 
course of FK506 treatment early in the posttransplantation 
period markedly reduced the number of inflammatory cells. 
The allograft reaction in the heart consists of a diffuse, rapidly 
progressive mononuclear infiltration of the myocardium. By 
day 6, the inflammatory reaction had caused sufficient damage 
to the myocardium so that the graft ceased to function (Fig. 
IA). In contrast, the hearts in FK506-treated animals only had 
a mild scattering of lymphocytes in the myocardium and no 
myocardial damage (Fig. IB). 
A short course of FK506 also greatly reduced the intensity 
of the cellular infiltration in liver allografts. By day 7, the 
untreated animals had an intense mononuclear infiltration of 
the periportal areas and a diffuse infiltration of the sinusoids 
(Fig. IC). The allografts in the treated animals had a mild-to-
moderate periportal inflammation (Fig. ID) that decreased 
spontaneously with time. 
DISCUSSION 
The ACI and LEW strain combinations used for these ex-
periments are strongly histoincompatible and differ for both 
MHC (RTI) and non-MHC histocompatibility genes. The ef-
fect of allograft acceptance under a longer course of FK506 
therapy has been shown to be specific for the donor strain (5, 
6). The same kind of short-course treatment, even as late as 4 
days after transplantation, induced permanent acceptance of 
practically all liver grafts. The greater ease with which liver 
graft survival could be accomplished compared to the heart is 
consistent with much work showing a slight biologic advantage 
for hepatic grafts (21-24). 
With either the liver or heart, the ability of FK506 to switch 
off the destructive immune process, practically on the eve of 
rejection, was extraordinary. The same thing has been accom-
plished occasionally in dog liver recipients with a few doses of 
antilymphocyte serum (25), and rather easily in canine recipi-
ents of livers and kidneys under FK506 treatment (11). How-
ever, liver graft acceptance in larger animals usually is not 
permanent. An explanation for permanent graft acceptance 
without further treatment may require revision of some of the 
classic theories of rejection and immunosuppression as has 
been discussed in another communication (18). 
A conventional view might hold that FK506 disrupts the 
recognition and/or the early induction phase of the allograft 
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FIG UR E 1. A. Untreated heart graft at day 5 showing mononuclear 
infiltration and interstitial edema of the myocardium . B. FK 506-treated 
heart graft at day 5; i.m. FK506 was s tarted on day 4; note mild 
sca t tered mononuclear infilt.ratio n. C. Untreated liver graft at day 7 
with intense mononuclear cell infiltration of portal tracts and sinusoids 
response and does not effect the proliferation of activated T 
cells, preventing thereby an amplification effect by cytokines 
and other mediators. Recent molecular biological study reveals 
that FK506 inhibits mRNA accumulation and transcription of 
early-phase T cell activation genes, such as IL-2, IL-3, IL-4, 
and gamma-IFN (26). If this explanation were true, it is hard 
to understand how treatment begun 4 or 5 days after exposure 
to the alloantigens could be so effective. The astonishing ability 
of FK506 to stop advanced and refractory rejection in human 
liver grafts (13) may be a clinical analogue to the animal 
observations. 
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